Yelin Lapidot Holdings Management Ltd. Grows Holdings in InMode Ltd. (NASDAQ:INMD)

Yelin Lapidot Holdings Management Ltd. grew its stake in shares of InMode Ltd. (NASDAQ:INMD) by 14.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 283,024 shares of the healthcare company’s stock after buying an additional 35,650 shares during the quarter. InMode accounts for 1.5% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 18th biggest position. Yelin Lapidot Holdings Management Ltd. owned 0.34% of InMode worth $6,294,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in INMD. Aigen Investment Management LP raised its position in InMode by 22.9% during the fourth quarter. Aigen Investment Management LP now owns 12,572 shares of the healthcare company’s stock valued at $280,000 after purchasing an additional 2,341 shares in the last quarter. Trexquant Investment LP bought a new stake in InMode in the 4th quarter worth approximately $826,000. D.A. Davidson & CO. boosted its stake in InMode by 8.1% in the fourth quarter. D.A. Davidson & CO. now owns 31,405 shares of the healthcare company’s stock worth $698,000 after buying an additional 2,360 shares in the last quarter. Norges Bank bought a new position in InMode during the fourth quarter valued at approximately $8,890,000. Finally, First National Advisers LLC raised its stake in shares of InMode by 26.8% during the fourth quarter. First National Advisers LLC now owns 26,343 shares of the healthcare company’s stock worth $586,000 after acquiring an additional 5,566 shares in the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Price Performance

NASDAQ:INMD traded up $0.03 during mid-day trading on Friday, hitting $18.48. 921,840 shares of the company’s stock were exchanged, compared to its average volume of 1,176,980. InMode Ltd. has a one year low of $16.72 and a one year high of $48.25. The business has a fifty day moving average price of $18.88 and a 200 day moving average price of $21.20. The company has a market cap of $1.55 billion, a PE ratio of 8.76 and a beta of 2.20.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Thursday, May 2nd. The healthcare company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.09. InMode had a return on equity of 26.15% and a net margin of 38.84%. The company had revenue of $80.28 million for the quarter, compared to the consensus estimate of $80.10 million. On average, equities analysts forecast that InMode Ltd. will post 1.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on INMD. Barclays cut their price objective on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, April 12th. UBS Group raised their price objective on InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, February 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.